Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
about
Therapeutic monoclonal antibodies and clinical laboratory tests: When, why, and what is expected?Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.Glycan and Peptide IgE Epitopes of the TNF-alpha Blockers Infliximab and Adalimumab - Precision Diagnostics by Cross-Reactivity Immune Profiling of Patient Sera.Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.Defining and characterizing sustained remission in patients with rheumatoid arthritis.Drug survival rates and reasons for drug discontinuation in psoriasis.Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database.Natural Conformational Sampling of Human TNFα Visualized by Double Electron-Electron Resonance.The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease."Drug-Survival"-Raten und Gründe für den Abbruch von Systemtherapien bei Psoriasis.Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
P2860
Q38623790-B6FD8EF8-F0F3-4464-9C2A-081806123CD9Q40081220-CBF96086-B59D-4FCC-80E8-3CA828FBCC87Q45074275-ED66A896-1AEF-4445-8A8C-B151484E20ABQ46271418-A9124452-06AE-4790-BAA5-F8ED823AB3D4Q47336584-1BDB819F-EA47-485C-BB02-CA7B6400FFDAQ47624590-14A5F6BF-6210-43EE-91A2-FA904FE34732Q47693399-E05974FD-B544-4344-980F-36732444DAB1Q47705810-ECA6498B-3B07-43A0-A9EB-1F502BBF41B9Q48024823-285783B4-DDAD-4026-9956-21D77131F546Q48194119-9DE25FC5-C0C9-4A06-B148-76D16BCF082AQ52844749-1283292E-DD0B-408A-9FEF-9F647DF1596CQ54978927-9012AF8C-B11C-44EA-ACA2-15BE4D39907CQ55008089-17B88ACF-FF6F-4B4B-ADF1-189AABBA90F9Q55310713-FA2B3DFA-22D1-4D5C-A52A-6461026EF676Q59129976-B54CFD0D-FC83-4F68-9CAD-BD25D807E6C0
P2860
Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Immunogenicity of infliximab a ...... erapeutic efficacy and safety?
@en
type
label
Immunogenicity of infliximab a ...... erapeutic efficacy and safety?
@en
prefLabel
Immunogenicity of infliximab a ...... erapeutic efficacy and safety?
@en
P2093
P2860
P1476
Immunogenicity of infliximab a ...... erapeutic efficacy and safety?
@en
P2093
Andrea Guastalla
Elena Penza
Francesca Spanò
Francesco Puppo
Giuseppe Murdaca
Miriam Contatore
Ottavia Magnani
P2860
P356
10.1517/14740338.2016.1112375
P407
P577
2015-11-11T00:00:00Z